Third Arc Bio Announces $52M Series A Extension to Expand Oncology and Immunology & Inflammation Portfolio
PR Newswire —
$52M equity adds to previously announced $165M Series A New investor Andreessen Horowitz (a16z) leads the financing with founding investor Omega Funds; additional investors include Life Sciences at Goldman Sachs Alternatives, BVF Partners LP, funds managed by abrdn. Inc., accounts advised...